The Future of Endocannabinoid Research After the CB1 Blocker Rimonabant Was Pulled from Market | Research

The takeaway

After rimonabant (a CB1 receptor blocker for obesity) was withdrawn due to psychiatric side effects, the authors argued for continued endocannabinoid research with better safety safeguards rather than abandoning the field.

Read this if you are interested in why blocking the endocannabinoid system caused psychiatric problems and what it means for future drug development.

Four major pharma companies abandoned CB1 antagonist research after rimonabant withdrawal

What the researchers found

Rimonabant, the first clinically available CB1 receptor antagonist, showed promise for treating obesity, metabolic syndrome, and potentially drug addiction. However, it was linked to increased risk of anxiety, depression, and suicidality.

The European Medicines Agency called for its withdrawal in October 2008. Shortly after, several major pharmaceutical companies (Sanofi-Aventis, Merck, Pfizer, Solvay) announced they would stop clinical research on this drug class entirely.

The authors argued against abandoning the field, suggesting that the endocannabinoid system has therapeutic potential for many conditions beyond obesity. They made recommendations for continuing research with improved safety measures to protect patients and clinical trial subjects.

Why it matters

The rimonabant story illustrates the risks and complexities of targeting the endocannabinoid system. The psychiatric side effects highlighted that blocking cannabinoid receptors can have serious mental health consequences, influencing how the field approached subsequent drug development.

The numbers in context

Rimonabant was withdrawn in October 2008. At least four major pharmaceutical companies stopped CB1 antagonist research: Sanofi-Aventis, Merck, Pfizer, and Solvay.

How the study worked

Commentary/review discussing the rimonabant withdrawal and providing recommendations for the future of endocannabinoid-targeted clinical research.

What this study cannot tell us

This was a commentary piece rather than original research. The recommendations were opinion-based, though informed by the clinical evidence that led to rimonabant withdrawal.

How to read the evidence

Expert commentary and review, not original research. Provides important context for the field but represents opinion informed by clinical evidence.

When this study was published

Published in 2009, shortly after rimonabant withdrawal. Peripheral CB1 antagonists that do not cross the blood-brain barrier have since been explored as a safer alternative approach.

The bigger picture

The rimonabant episode was a watershed moment for endocannabinoid pharmacology. It demonstrated that the endocannabinoid system plays a crucial role in mood regulation, and that blocking it carries psychiatric risks. This has influenced subsequent approaches to endocannabinoid-targeted drug development.

Questions still open

Can peripherally restricted CB1 antagonists (that do not enter the brain) provide metabolic benefits without psychiatric risk? Should the endocannabinoid system be targeted through enzyme inhibition rather than receptor blockade? What safety monitoring is needed for future endocannabinoid-targeted drugs?

Common questions

What was rimonabant and why was it withdrawn?

Rimonabant was a drug that blocked CB1 cannabinoid receptors, approved in Europe for obesity treatment. It was withdrawn because users had increased rates of anxiety, depression, and suicidal thoughts, demonstrating that the endocannabinoid system plays an important role in mood regulation.

Does this mean the endocannabinoid system cannot be targeted for obesity?

Not necessarily. The psychiatric side effects were likely caused by blocking CB1 receptors in the brain. Newer approaches focus on CB1 antagonists that stay outside the brain (peripheral restriction) to target metabolic effects while avoiding psychiatric risks.

Read the original research

The future of endocannabinoid-oriented clinical research after CB1 antagonists.

Psychopharmacology, 205(1), 171-4

View on PubMed ↗Publisher’s paper ↗

Citation

Le Foll, Bernard; Gorelick, David A; Goldberg, Steven R. (2009). The future of endocannabinoid-oriented clinical research after CB1 antagonists.. Psychopharmacology, 205(1), 171-4. https://doi.org/10.1007/s00213-009-1506-7